| 000 | 01814 a2200565 4500 | ||
|---|---|---|---|
| 005 | 20250518085842.0 | ||
| 264 | 0 | _c20210514 | |
| 008 | 202105s 0 0 eng d | ||
| 022 | _a2045-7634 | ||
| 024 | 7 |
_a10.1002/cam4.2932 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aShabto, Julie M | |
| 245 | 0 | 0 |
_aNovel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors. _h[electronic resource] |
| 260 |
_bCancer medicine _c04 2020 |
||
| 300 |
_a2752-2760 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmune Checkpoint Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aLiver Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aRisk Assessment _xmethods |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aUrologic Neoplasms _xdrug therapy |
| 700 | 1 | _aMartini, Dylan J | |
| 700 | 1 | _aLiu, Yuan | |
| 700 | 1 | _aRavindranathan, Deepak | |
| 700 | 1 | _aBrown, Jacqueline | |
| 700 | 1 | _aHitron, Emilie E | |
| 700 | 1 | _aRussler, Greta A | |
| 700 | 1 | _aCaulfield, Sarah | |
| 700 | 1 | _aKissick, Haydn | |
| 700 | 1 | _aAlemozaffar, Mehrdad | |
| 700 | 1 | _aOgan, Kenneth | |
| 700 | 1 | _aHarris, Wayne B | |
| 700 | 1 | _aMaster, Viraj A | |
| 700 | 1 | _aKucuk, Omer | |
| 700 | 1 | _aCarthon, Bradley C | |
| 700 | 1 | _aBilen, Mehmet A | |
| 773 | 0 |
_tCancer medicine _gvol. 9 _gno. 8 _gp. 2752-2760 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cam4.2932 _zAvailable from publisher's website |
| 999 |
_c30675071 _d30675071 |
||